ASTRO: SBRT Prolongs Survival in Non-Small-Cell Lung Cancer

Share this content:
ASTRO: SBRT Prolongs Survival in Non-Small-Cell Lung Cancer
ASTRO: SBRT Prolongs Survival in Non-Small-Cell Lung Cancer

THURSDAY, Sept. 28, 2017 (HealthDay News) -- For patients with stage IV non-small-cell lung cancer (NSCLC), consolidative stereotactic body radiation therapy (SBRT) before maintenance chemotherapy is associated with significant improvement in progression-free survival, according to a study presented at the annual meeting of the American Society for Radiation Oncology (ASTRO), held from Sept. 24 to 27 in San Diego.

Puneeth Iyengar, M.D., Ph.D., from the University of Texas Southwestern Medical Center in Dallas, and colleagues randomized patients with stage IV NSCLC who achieved a partial response or stable disease to induction chemotherapy with six or fewer sites of limited metastatic disease to maintenance chemotherapy (15 patients) or consolidative SBRT to all sites of disease followed by maintenance chemotherapy (14 patients).

The researchers stopped the trial early after an unplanned interim analysis identified significant improvement in progression-free survival in the SBRT plus maintenance chemotherapy arm versus the chemotherapy alone arm (9.7 versus 3.5 months). Similar toxicity was seen in both arms. No in-field failures were seen, and there were fewer overall recurrences in the SBRT arm.

"The addition of radiation therapy directed at each of the cancerous areas greatly improved how patients responded to subsequent rounds of chemotherapy," Iyengar said in a statement. "This finding suggests that local treatments, including radiation, could work in concert with chemotherapy to prolong the amount of time before recurrence occurs in patients with limited sites of metastatic NSCLC."

News Release/Abstract
More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Jury Awards 4.62B in Johnson  Johnson Talcum Powder Lawsuit

Jury Awards $4.62B in Johnson & Johnson Talcum ...

The award includes $550 million in compensatory damages and $4.14 billion in punitive damages

100 Now Sickened by Salmonella-Tainted Honey Smacks Cereal

100 Now Sickened by Salmonella-Tainted Honey Smacks Cereal

Thirty people have been hospitalized, but no deaths have been reported

Data Support FDA Restrictions on Child Cough and Cold Medicines

Data Support FDA Restrictions on Child Cough and ...

Surveillance data showed more adverse events for children exposed to hydrocodone than codeine

is free, fast, and customized just for you!




Already a member?

Sign In Now »